Maria E. Arango

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text

Tumor Biology, C-met Kinase, Chemoprevention Strategy +15

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

James G. Christensen, Helen Y. Zou, Maria E. Arango et al. · Molecular Cancer Therapeutics · 2007 · 642 citations

Signal Transducers, Immunology, Cell Death +23

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Alessandra Blasina, Jill Hallin, Enhong Chen et al. · Molecular Cancer Therapeutics · 2008 · 226 citations · Full text

Molecular Biology, Cell Death, Cell Cycle +16

Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

Shari A. Price‐Schiavi, Scott Jepson, Peter Li et al. · International Journal of Cancer · 2002 · 206 citations · Full text

Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways

Scott Jepson, Masanobu Komatsu, Bushra Haq et al. · Oncogene · 2002 · 135 citations

Intramembrane Erbb2 Ligand, Signal Transduction, Signaling Pathway +9